These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 35303962)

  • 41. Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review).
    Peng X; Chen L; Chen L; Wang B; Wang Y; Zhan X
    Exp Ther Med; 2021 Apr; 21(4):340. PubMed ID: 33732313
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development.
    Bashiri Dezfouli A; Yazdi M; Pockley AG; Khosravi M; Kobold S; Wagner E; Multhoff G
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.
    Zhang C; Oberoi P; Oelsner S; Waldmann A; Lindner A; Tonn T; Wels WS
    Front Immunol; 2017; 8():533. PubMed ID: 28572802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current Progress of CAR-NK Therapy in Cancer Treatment.
    Pang Z; Wang Z; Li F; Feng C; Mu X
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
    Sabbah M; Jondreville L; Lacan C; Norol F; Vieillard V; Roos-Weil D; Nguyen S
    Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions.
    Arias J; Yu J; Varshney M; Inzunza J; Nalvarte I
    Stem Cells Transl Med; 2021 Jul; 10(7):987-995. PubMed ID: 33634954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox.
    Xiao J; Zhang T; Gao F; Zhou Z; Shu G; Zou Y; Yin G
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428748
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges.
    Wang L; Dou M; Ma Q; Yao R; Liu J
    Int Immunopharmacol; 2019 Sep; 74():105695. PubMed ID: 31254958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy.
    Fabian KP; Hodge JW
    Mol Ther Oncolytics; 2021 Dec; 23():266-276. PubMed ID: 34761106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy.
    Wendel P; Reindl LM; Bexte T; Künnemeyer L; Särchen V; Albinger N; Mackensen A; Rettinger E; Bopp T; Ullrich E
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33807011
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NK cells and ILCs in tumor immunotherapy.
    Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
    Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments.
    Lee S; Kim TD
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
    Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology.
    Gunduz M; Ataca Atilla P; Atilla E
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
    Liu E; Tong Y; Dotti G; Shaim H; Savoldo B; Mukherjee M; Orange J; Wan X; Lu X; Reynolds A; Gagea M; Banerjee P; Cai R; Bdaiwi MH; Basar R; Muftuoglu M; Li L; Marin D; Wierda W; Keating M; Champlin R; Shpall E; Rezvani K
    Leukemia; 2018 Feb; 32(2):520-531. PubMed ID: 28725044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.